Project Grant R01AI194296
Award Date 9/3/25
Completion Date 8/31/30
Dollars Obligated $677K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $314,363 Project Grant was awarded on September 11, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit company based in Austin, Texas. The grant supports the development of a microneedle-based mRNA flu vaccine for transcutaneous immunization. The goal is to create a stable, patient-friendly influenza vaccine delivered through the skin rather than by...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $929,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) on July 23, 2025. The grant supports research to investigate the mechanism of action of different vaccine platforms, including mRNA-based and Newcastle Disease Virus (NDV)-based vaccines, in inducing long-lasting protective systemic and mucosal immune responses against...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $197,640 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on July 16, 2025. This grant supports research to investigate the contribution of a novel monocyte transcriptional state, termed Monocyte Substate 1 (MS1), to sepsis immunopathogenesis and patient heterogeneity. The project will...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $101,982 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMMS) to conduct research on the "Temporal Regulation of mRNA Biogenesis in Immune Responses." This 21-month project, running from May 2025 to February 2027, seeks to uncover mechanistic insights into the regulation and impact of stimulus-induced immune mRNA...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...
- This Cooperative Agreement award, valued at $1,673,641.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal is to evaluate a novel mRNA-based SARS-CoV-2 vaccine candidate that incorporates a multi-organ protection (MOP) sequence and an mRNA-encoded molecular adjuvant (IL-12p70) to enhance immune responses, particularly in older individuals. The project involves a two-stage clinical...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- This $2,710,680 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to develop new generation mRNA-based vaccines for tuberculosis (TB). The goals are to: 1) develop mRNA vaccines expressing protective TB antigens combined with self-adjuvant peptides, 2) characterize the molecular mechanisms of the new mRNA vaccines, and 3) determine the efficacy of the vaccines against TB in mice....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, titled "Role of ZNF Proteins in the Establishment and Maintenance of HIV Latency", will support research to evaluate the role of zinc finger (ZNF) proteins in establishing and maintaining HIV-1 reservoirs through...